- Trials with a EudraCT protocol (75)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
75 result(s) found for: mpn.
Displaying page 1 of 4.
EudraCT Number: 2022-001076-34 | Sponsor Protocol Number: ABNL-MARRO-001 | Start Date*: 2023-06-12 | ||||||||||||||||
Sponsor Name:Theradex (Europe) Ltd. | ||||||||||||||||||
Full Title: The ABNL-MARRO 001 Study: A Phase 1/2 Study of Active Myeloid Target Compound Combinations in MDS/MPN Overlap Syndromes | ||||||||||||||||||
Medical condition: Myelodysplastic syndrome/Myeloproliferative Neoplasm Overlap Syndromes | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003986-20 | Sponsor Protocol Number: LUCAS | Start Date*: 2021-09-06 | |||||||||||
Sponsor Name:Leipzig University | |||||||||||||
Full Title: A Phase II, Open-Label, Multicenter Study of Orally Administered CA-4948 for the Treatment of Anemia in Patients with Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) | |||||||||||||
Medical condition: Anemia in patients with very low, low or intermediate risk myelodysplastic syndromes (MDS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2022-003009-31 | Sponsor Protocol Number: HH007 | Start Date*: 2022-12-23 | |||||||||||
Sponsor Name:Zealand University Hospital, dept. of Haematology | |||||||||||||
Full Title: Atorvastatin for patients with Philadelphia-negative chronic myeloproliferative neoplasms - Essential thrombocythemia, polycythemia vera and prefibrotic myelofibrosis | |||||||||||||
Medical condition: Essential thrombocythemia, Polycythemia vera, prefibrotic myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001406-42 | Sponsor Protocol Number: 30032016 | Start Date*: 2016-12-20 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:Hæmatologisk Afdeling, Sjælland Sygehus, Roskilde | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Statin- and bisphosphonate treatment in patients with the Philadelphia-negative chronic myeloproliferative neoplasms - essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: The Philadelphia-negative chronic myeloproliferative neoplasms: Essential thrombocytosis, polycythemia vera and hypercellular myelofibrosis. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DK (Prematurely Ended) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2018-001203-36 | Sponsor Protocol Number: BHT-II-002 | Start Date*: 2019-01-09 | ||||||||||||||||
Sponsor Name:4D Pharma Plc | ||||||||||||||||||
Full Title: A Phase 2 Randomised, Double Blind, Placebo Controlled, Parallel Group, Multicentre Study to Evaluate the Safety and Efficacy of Repeated Oral Doses of Blautix™ in Adult Subjects with Irritable Bow... | ||||||||||||||||||
Medical condition: Irritable Bowel Syndrome (IBS), subtypes IBS-C and IBS-D | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: IE (Completed) GB (Completed) PL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-002132-25 | Sponsor Protocol Number: 12-181 | Start Date*: 2015-06-29 |
Sponsor Name:RWTH Aachen University, represented by the Rector, himself represented by the Dean of the Medical Faculty | ||
Full Title: RUXOlitinib versus BEst Available Therapy in patients with high-risk polycythemia vera or high-risk essential thrombocythemia – The RUXO-BEAT Trial | ||
Medical condition: Myeloproliferative Neoplasms (MPN): high-risk Polycythemia Vera (PV) and high-risk Essential Thrombocythemia (ET) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004874-41 | Sponsor Protocol Number: NMDSG14A | Start Date*: 2016-07-25 |
Sponsor Name:Nordic MDS study group | ||
Full Title: Safety, Efficacy and Immune Response of Histamine Dihydrochloride and Low-dose Interleukin-2 in Chronic Myelomonocytic Leukemia (CMML) | ||
Medical condition: Chronic myelomonocytic leukemia | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-000607-36 | Sponsor Protocol Number: ACE-536-MF-002 | Start Date*: 2021-06-01 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||||||||||||||||||||||
Full Title: A PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF LUSPATERCEPT (ACE-536) VERSUS PLACEBO IN SUBJECTS WITH MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED MYELOFIBROSIS ON CONCOM... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Ongoing) FR (Ongoing) CZ (Completed) AT (Ongoing) IE (Ongoing) GR (Ongoing) BE (Ongoing) IT (Ongoing) HU (Ongoing) | ||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002281-23 | Sponsor Protocol Number: Spon1345-14 | Start Date*: 2016-06-13 | |||||||||||
Sponsor Name:Cardiff University | |||||||||||||
Full Title: A phase 2 study of the monocyte-targeted histone deacetylase inhibitor tefinostat (CHR-2845) in chronic myelomonocytic leukaemia (CMML) | |||||||||||||
Medical condition: Chronic myelomonocytic leukaemia (CMML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-002431-29 | Sponsor Protocol Number: POMINC(MPNSG02-12) | Start Date*: 2013-07-23 |
Sponsor Name:University Hospital of Ulm | ||
Full Title: A Phase-Ib/II Study of Ruxolitinib and Pomalidomide Combination Therapy in Patients with Primary and Secondary Myelofibrosis | ||
Medical condition: Patients with Primary and Secondary Myelofibrosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Restarted) | ||
Trial results: (No results available) |
EudraCT Number: 2019-001201-24 | Sponsor Protocol Number: KRT-232-104 | Start Date*: 2019-12-02 | |||||||||||
Sponsor Name:Kartos Therapeutics, Inc. | |||||||||||||
Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined with Low-Dose Cytarabine (LDAC) or Decitabine in Patients with Acute Myeloid Leukemia (AML). | |||||||||||||
Medical condition: Relapsed or refractory AML, AML secondary to myeloproliferative neoplasms (MPN), and JAK2 mutationpositive AML. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) DE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) HU (Completed) PL (Completed) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-002318-37 | Sponsor Protocol Number: INCB18424-357 | Start Date*: 2012-11-06 |
Sponsor Name:Incyte Corporation | ||
Full Title: Polycythemia Vera Symptom Study Evaluating Ruxolitinib Versus Hydroxyurea in a Randomized, Multicenter, Double-Blind, Double-Dummy, Phase 3 Efficacy and Safety Study of Patient Reported Outcomes | ||
Medical condition: Polycythemia Vera | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) BE (Completed) IT (Completed) ES (Completed) IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-000322-35 | Sponsor Protocol Number: ACE-536-MF-001 | Start Date*: 2017-08-22 | ||||||||||||||||||||||||||||||||||||
Sponsor Name:Celgene Corporation | ||||||||||||||||||||||||||||||||||||||
Full Title: A Phase 2, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Luspatercept (ACE-536) in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis and Anemia With and With... | ||||||||||||||||||||||||||||||||||||||
Medical condition: Anemia associated with myeloproliferative neoplasm (MPN)-associated myelofibrosis | ||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IT (Ongoing) | ||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-004239-21 | Sponsor Protocol Number: PAC325 | Start Date*: 2012-12-03 | |||||||||||
Sponsor Name:CTI BioPharma Corp. | |||||||||||||
Full Title: A Randomized Controlled Phase 3 Study of Oral Pacritinib versus Best Available Therapy in Patients with Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemi... | |||||||||||||
Medical condition: Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) GB (Completed) CZ (Prematurely Ended) HU (Prematurely Ended) DE (Completed) IT (Temporarily Halted) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001048-40 | Sponsor Protocol Number: B1371013 | Start Date*: 2015-02-10 | |||||||||||
Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, 10017 | |||||||||||||
Full Title: A phase 2, double-blind, randomized safety and efficacy study of Glasdegib (PF-04449913) versus placebo in patients with Myelofibrosis previously treated with ruxolitinib. | |||||||||||||
Medical condition: Myelofibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) AT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005497-38 | Sponsor Protocol Number: RG_15-234 | Start Date*: 2016-05-25 | |||||||||||
Sponsor Name:University of Birmingham | |||||||||||||
Full Title: Effects of TAMoxifen on the Mutant Allele Burden and Disease Course in Patients with MyeloprolifeRatIve Neoplasms | |||||||||||||
Medical condition: Myeloproliferative Neoplasms | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-004370-10 | Sponsor Protocol Number: RUXO_LMMC-PRO_1401 | Start Date*: 2014-03-21 | |||||||||||
Sponsor Name:Grupo Español de Sindromes Mielodisplásicos (GESMD) | |||||||||||||
Full Title: A phase II study of ruxolitinib (INCB018424) to evaluate efficacy and safety in Patients with Proliferative Chronic Myelomonocytic Leukemia (CMML) | |||||||||||||
Medical condition: Proliferative Chronic Myelomonocytic Leukemia (CMML) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-002452-37 | Sponsor Protocol Number: IMG-7289-CTP-202 | Start Date*: 2022-01-27 | |||||||||||
Sponsor Name:Imago BioSciences Inc. | |||||||||||||
Full Title: A Multi-Center, Open Label, Extension Study Evaluating the Safety and Efficacy of Bomedemstat for the Treatment of Patients with Myeloproliferative Neoplasms (MPNs) Enrolled in a Prior Bomedemstat ... | |||||||||||||
Medical condition: Patients with Myeloproliferative Neoplasms (MPNs) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-010738-23 | Sponsor Protocol Number: MPN-SG01-09 | Start Date*: 2009-11-12 |
Sponsor Name:Universitätsklinikum Ulm | ||
Full Title: Multi-Center Phase II Study with Pomalidomide in Patients with Myeloproliferative Neoplasms in Fibrotic Stage | ||
Medical condition: This is a phase II, multi-center study of pomalidomide in adult patients with Primary myelofibrosis, Secondary myelofibrosis, and unclassifiable Myeloproliferative Neoplasms showing at least grade ... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-001847-58 | Sponsor Protocol Number: ARD12042 | Start Date*: 2011-10-12 | |||||||||||
Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
Full Title: A Randomized Phase II, Open-Label study of the Efficacy and Safety of Orally Administered SAR302503 in patients with polycythemia vera (PV) or essential thrombocythemia (ET) who are resistant or in... | |||||||||||||
Medical condition: polycythemia vera, or essential thrombocythemia | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) GB (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
